Vadim Koshkin, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Pennsylvania, Philadelphia, PABA05/2007Cognitive Science
    University of Chicago, Pritzker School of Medicine, Chicago, ILMD06/2012Medicine
    University of Michigan, Ann Arbor, MI06/2015Internal Medicine Residency
    Cleveland Clinic, Cleveland, OH06/2018Hematology/Oncology Fellowship
    Collapse Awards and Honors
    Bladder Cancer Advocacy Network (BCAN)2017John Quale Travel Fellowship Award
    Kidney Cancer Association2017Young Investigator Abstract Award
    Conquer Cancer Foundation2017Abstract Merit Award
    AACR/ASCO2016Methods in Clinical Cancer Research Workshop Participant
    Conquer Cancer Foundation 2015Abstract Merit Award

    Collapse Overview 
    Collapse Overview
    I am a genitourinary medical oncologist and in this capacity I specialize in caring for patients with bladder, prostate, kidney and testicular cancers. My focus is in clinical and translational research in bladder and prostate cancers, in particular the design and implementation of clinical trials for patients with these malignancies and the discovery and validation of novel biomarkers and treatment targets.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. Future Oncol. 2020 Sep 17. Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF, Van Der Heijden MS, Koshkin VS, Pook DW, Özgüroglu M, Santiago L, Zhong B, Chien D, Lin W, Tagliaferri MA, Loriot Y. PMID: 32938232.
      View in: PubMed   Mentions:    Fields:    
    2. Sequencing of PD-1/L1 Inhibitors and Carboplatin-Based Chemotherapy for Cisplatin-Ineligible Metastatic Urothelial Carcinoma. J Urol. 2020 Sep 16; 101097JU0000000000001371. Wei XX, Werner L, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, Szabados B, Morrison L, Powles T, Carril-Ajuria L, Castellano D, Velho PI, Hahn NM, McKay RR, Raggi D, Necchi A, Kanesvaran R, Alerasool P, Gaines J, Galsky M, Bellmunt J, Sonpavde G. PMID: 32935617.
      View in: PubMed   Mentions:    Fields:    
    3. Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. Invest New Drugs. 2019 06; 37(3):559-566. Koshkin VS, Mir MC, Barata P, Gul A, Gupta R, Stephenson AJ, Kaouk J, Berglund R, Magi-Galluzzi C, Klein EA, Dreicer R, Garcia JA. PMID: 31037562.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    4. Systematic Review: Targeting HER2 in Bladder Cancer. Bladder Cancer. 2019; 5(1):1-12. Koshkin VS, O’Donnell P, Yu EY, Grivas P. View Publication.
    5. Translational Cancer Research. The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape. 2018. Koshkin VS, Basu A, Grivas P. View Publication.
    6. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Ther Adv Urol. 2018 Dec; 10(12):445-454. Koshkin VS, Small EJ. PMID: 30574205.
      View in: PubMed   Mentions:
    7. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clin Cancer Res. 2019 01 01; 25(1):210-221. Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P. PMID: 30327311.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    8. Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):413-419.e1. Barata PC, Mendiratta P, Kotecha R, Gopalakrishnan D, Juloori A, Chao ST, Koshkin V, Ornstein M, Gilligan TD, Wood LS, Rini BI, Angelov L, Garcia JA. PMID: 30172552.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. J Clin Invest. 2018 08 01; 128(8):3333-3340. Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, Tyler A, Berk MP, Hu B, Hwang TH, Figg WD, Peer CJ, Chien C, Koshkin VS, Mendiratta P, Grivas P, Rini B, Garcia J, Auchus RJ, Sharifi N. PMID: 29939161.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. Prostate. 2018 09; 78(13):1035-1041. Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA. PMID: 29882332.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag. 2018; 14:1019-1040. Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P. PMID: 29892196.
      View in: PubMed   Mentions:
    12. Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research. Transl Androl Urol. 2018 Jun; 7(3):504-507. Koshkin VS, Grivas P. PMID: 30050808.
      View in: PubMed   Mentions:
    13. Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. Target Oncol. 2018 06; 13(3):353-361. Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P. PMID: 29623487.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Targeted Oncology. Future Directions of Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer. 2018. Koshkin VS, Grivas P. View Publication.
    15. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. Curr Oncol Rep. 2018 04 11; 20(6):48. Koshkin VS, Grivas P. PMID: 29644490.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    16. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. Clin Genitourin Cancer. 2018 08; 16(4):e879-e892. Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P. PMID: 29576445.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018 01 29; 6(1):9. Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI. PMID: 29378660.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    18. Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. Clin Genitourin Cancer. 2018 04; 16(2):e437-e442. Zahoor H, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, Garcia JA, Rini B, Grivas P. PMID: 29154041.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    19. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol. 2017 Oct 01; 28(10):2458-2463. Barata PC, Koshkin VS, Funchain P, Sohal D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, Garcia J, Rini B, Grivas P. PMID: 28945843.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    20. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. Eur Urol Focus. 2019 03; 5(2):242-249. Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K. PMID: 28753897.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma? Ann Oncol. 2017 04 01; 28(4):680-682. Grivas P, Koshkin VS, Pal SK. PMID: 28328001.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. J Clin Oncol. 2016 Oct 20; 34(30):3680-3685. Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH. PMID: 27573658.
      View in: PubMed   Mentions: 6     Fields:    
    23. Emerging therapeutics in refractory renal cell carcinoma. Expert Opin Pharmacother. 2016 Jun; 17(9):1225-32. Koshkin VS, Rini BI. PMID: 27112171.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    24. CAD-associated reader error in CT colonography. Acad Radiol. 2012 Jul; 19(7):801-10. Koshkin VS, Hinshaw JL, Wroblewski K, Dachman AH. PMID: 22537502.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Caspase-mediated cell death predominates following engraftment of neural progenitor cells into traumatically injured rat brain. Brain Res. 2005 Dec 14; 1065(1-2):8-19. Bakshi A, Keck CA, Koshkin VS, LeBold DG, Siman R, Snyder EY, McIntosh TK. PMID: 16309635.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    Vadim's Networks
    Concepts (101)
    Derived automatically from this person's publications.
    Co-Authors (3)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department